Dr. Joseph James Maly, MD

Dr. Maly practices at Norton Hospital in Louisville, Kentucky, part of Norton Healthcare.

Dr. Maly's NPI, 1043502206, was assigned on May 6, 2011. Dr. Maly graduated from Temple University School of Medicine in 2011. Dr. Maly holds Kentucky license 50414.

Dr. Maly's primary practice is Norton Hospital, at 200 East Chestnut Street, Louisville, KY 40202 in Jefferson County. The practice phone is (502) 629-8000.

Dr. Maly's primary practice is Norton Hospital in Louisville, Kentucky, part of Norton Healthcare. Dr. Maly is also affiliated with Baptist Health Louisville. The medical group on file is Norton Cancer Institute. Dmand AI also links Dr. Maly to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maly practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Maly's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Maly is licensed in Kentucky.

CMS data shows 2,761 Medicare services from Dr. Maly across 12 procedure codes in 2024, for 638 Medicare patients. Medicare paid $178,801 for them.

CMS counts 638 Medicare patients who saw Dr. Maly in 2024. The largest group is 65 to 74, with 289 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maly's median patient age at 73, with 54% women.

In 2024, Dr. Maly wrote 2,106 Medicare Part D claims for 280 patients. 79% of them were for generic drugs. CMS names the drug for 1,740 of them, across 45 drugs with 11 or more claims each, at $3,754,699 in total drug cost. In 2023, CMS named 1,351 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Maly for performance year 2024, reported as part of a group. Dr. Maly accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Maly as offering telehealth.

Dmand AI links 16 papers to Dr. Maly, published from 2014 to 2025. 2017 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor and Cyclophosphamide. Dr. Maly has published most often in Future Oncol. Dr. Maly's most frequent co-authors are Kristie A. Blum, MD, Aref Al-Kali, MD and Ryan D. Cassaday, MD.

Dmand AI links Dr. Maly to 11 clinical trials, 3 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and COVID-19. Astex Pharmaceuticals, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Maly that name 3 trials.

CMS Open Payments shows 37 general payments to Dr. Maly from 16 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 75% of the total. Novartis Pharmaceuticals Corporation paid the most, $247. It also lists 44 research payments totaling $48,105 from 2021 to 2025, naming 3 clinical trials.

Dr. Maly graduated from Temple University School of Medicine in 2011.